Nouvèl

NEW YORK, 23 jen, 2022 (Globe Newswire)-ReportLinker.com anonse liberasyon an nan rapò a "Global Terapi nan venn ak nan venn aksè gwosè mache, pataje ak endistri tandans rapò analiz, pespektiv ak pwevwa pa itilizatè fen, aplikasyon, kalite, rejyon, 2022-2028" Fason ki pi rapid nan pénétrer likid nan diferan pati nan kò a se nan terapi IV.Art atak, konjesyon serebral, ak anpwazònman yo tout trete ak dwòg sa a. (IV) is a method of delivering medicines and fluids into the body through a vein.Medications containing vitamins and minerals are given by intravenous drip or intravenous injection, allowing the treatment to flow quickly through the bloodstream.According to Scope, IV administration is when the patient uses a tube called a cannula to put substances directly into a vein.This could be a side effect of a medication or a nutritional deficiency.IV therapy is the typical fason yo bay likid, dwòg, chimyoterapi, ak transfizyon san nan pasyan dezidrate.During administrasyon IV, divès kalite ekipman IV tankou katetè IV, ponp perfusion, aparèy imobilizasyon, ak twous administrasyon yo itilize. nan pwodwi chimik yo dwe apwovizyone nan kò a epi yo ka fasil pou kontwole. Terapi mondyal la nan venn ak nan venn aksè aparèy mache espere ogmante sou peryòd la prévision.The prévalence de dyabèt, k ap monte ensidans nan aksidan trafik, ak ogmantasyon nan pwosedi chirijikal yo atann yo pouse endistri a. COVID-19 has a positive overall impact on the IV therapy market.In patients with severe COVID-19-related acute respiratory distress syndrome, IV therapy (ARDS) is administered.For example, the use of intravenous immune globulin for the treatment of COVID-19 ARDS as an attractive adjuvant for the treatment of severe COVID-19-related ARDS was published in The Lancet Respiratory Medicine on November 11, 2021 because Li kapasite modile plizyè konpatiman iminitè ansanm.Se se konsa, ak ogmantasyon nan kantite pasyan ki gen COVID-19 ki gen rapò ak ARDS, demann lan pou terapi IV ak pwodwi aksè nan venn ogmante. Lifestyles tankou tansyon wo, dyabèt, obezite ak depresyon, mande pou swen entansif pandan rete nan lopital.Ovni pwochen ane yo kèk, chay la ogmante nan maladi kwonik tankou maladi kadyovaskilè, kansè, konjesyon serebral, ak dyabèt, makonnen ak yon popilasyon aje, yo bezwen an, epi yo te fè yon ti jan akizisyon yo, yo te fè yon ti jan pou yo fè fas a, yo te fè yon ti jan pou yo fè yo. se yo ki pami resous teknik ki kontribye nan pi an sekirite, pi wo-bon jan kalite terapi nan venn (IVT) pratik.Kòm teknoloji sante se yon disiplin konplèks, ak refleksyon ak diskisyon sou yon baz chak jou pa pwofesyonèl sante ki enplike nan swen pasyan nan inite a swen entansif, jaden an nan swen te sibi chanjman enpòtan yo se yon sèl ki gen rapò ak yo te yon sèl nan intwopa yo. Pratike.Market kontrent ponp manifakti mande pou règleman sevè ak enkyetid sou konplikasyon. The licensing process for new projects is being driven around pump production and consolidation.Additionally, rising product recalls due to manufacturing defects will slow the adoption of these therapies.For example, Fresenius Kabi recalled the Vigilant Agilia Drug Depot and Volumat MC Agilia Infusion Pump in August 2019 due to infusion alert issues, low-priority Keep Vein Open (KVO) and other software bugs.A major impediment to the growth of the industry is the complications associated with the use of IV methods and IV infusion products.End User Outlook Based on end user, the market is segmented into hospitals, ambulatory surgery centers, and clinics.The hospital segment will capture the largest revenue share in the intravenous (IV) treatment and venous access market in 2021.This is due to an increase in the number of surgeries performed compared to ambulatory surgery centers and Klinik. Envestisman.Aplikasyon pespektiv sou baz aplikasyon an, mache a se segmenté nan administrasyon dwòg, pwodwi ki baze Sepandan, sa a yo ta dwe rezève pou atlèt wo nivo ak yon istwa nan sentòm fò anba bon siveyans.Gen kèk atlèt ka benefisye de lè l sèvi avèk yon ekspansyon. ponp, zegwi ipodèrmik, pò implantable, ak lòt moun.Nan 2021, segman nan katetè nan venn pral pran pi gwo pataje nan revni nan terapi a nan venn (IV) ak mache aksè vèn. yon kavite kò oswa lumen.an katetè nan venn se yon katetè nan venn yo itilize delivre dwòg, likid, oswa lòt terapi dirèkteman nan san an.Yo yo pi souvan prezante nan yon venn nan bra a, byenke yo ka tou gen pou yo mete nan kou a, oswa nan men yo. segmenté nan Amerik di Nò, Ewòp, Azi Pasifik & Amerik Latin, Mwayen Oryan & Afrik.in 2021, Amerik di Nò se rejyon an ki mennen nan nan venn (IV) terapi ak mache aksè venen pa kaptire pi wo mache revni an. R & D Aktivite. Rapò rechèch sou mache a kouvri analiz de moun ki gen enterè kle yo nan mache yo.Major konpayi définissez nan rapò a gen ladan B. Braun Melsungen AG, Medtronic PLC, Terumo Corporation, Fresenius SE & Co. KGAA, Kadinal Sante, Inc., Pfizer, Inc. Inc. Deplwaye Estrateji nan terapi a nan venn (IV) ak mache aksè nan venn Mas 2022: Fresenius Kabi te siyen yon akò pou jwenn Fresenius Kabi, yon konpayi swen sante mondyal.Acuizition a, ki fèt yo entegre Iivenx 'Enhanced Systements Enfusion nan Fresenius Project Kabi nan Portfiolio nan Intraven. 2021: Baxter fòme patenarya ak US founisè teknoloji medikal Hillrom.Through kolaborasyon sa a, de konpayi yo vize yo pote ansanm de pi gwo biznis teknoloji medikal yo reyalize yon vizyon pataje nan transfòme swen sante mondyal ak amelyore swen pasyan.May 2021: Smith Medikal Fòm Partnership ak Teknoloji Medikal Konpayi ivenix. strategic investments in long-term partnerships designed to revolutionize mixing management and enhance patient health, while meeting the needs of healthcare providers.April 2021: B. Braun Medical launched a new program, Peripheral Advantage, to improve patients' experience with peripheral intravenous therapy.The program integrates clinical guidance, data-driven intuition, and improved tools to empower nurses to achieve first-hand success and help avoid the Konpleksite ki asosye ak periferik terapi IV.July 2019: Baxter resevwa US Manje ak Medikaman Administrasyon (FDA) apwobasyon pou myxredlin.Pwobasyon an pèmèt pou ensilin imedya pou perfusion nan venn nan lopital ak lòt anviwònman swen entansif epi ki gen yon ti kras etajè pou asire w ke yo te fè yon lòt moun nan lopital la. Centers • Clinics by Application • Medication Administration • Blood Products • Nutrients and Buffer Solutions • Diffusion Vessels by Type • Intravenous Catheters • Infusion Pumps • Hypodermic Needles • Implantable Ports • Other by Geography • North America o USo Canadao Mexico Rest of North America • Europe Germany o UKo France Russia Spain Italy o Rest of Europe • Asia Pacific China o Japan India Korea Singapore Malaysia o Rest of Azi Pasifik • Lameao Brezil Ajantin UAE Arabi Arabi Sid Nijerya Lamea Rest Konpayi Profile • B. Braun Melsungen AG • Medtronic Plc • Terumo Corporation • Fresenius SE & Co. KGAA • Kadinal Sante, Inc. Ofri • Kouvèti konplè • Pifò tab mache vaste & done • abònman ki baze sou modèl ki disponib • Pi bon pri garanti • garanti rechèch pòs-sale te apiye nan 10% personnalisation Li rapò an plen pou gratis: https: // www .reportLinker.com/P06283441/? Ganize dènye done endistri yo pou ou ka jwenn tout rechèch sou mache a ou bezwen touswit nan yon sèl kote .______________________________